In the quest to outshine the broader market, stock pickers diligently seek out stocks with the potential for superior performance. Making the right choices can significantly elevate your wealth.
The price of Biodesix Inc (NASDAQ: BDSX) closed at $0.44 in the last session, up 5.05% from day before closing price of $0.42. In other words, the price has increased by $5.05 from its previous closing price. On the day, 58.66 million shares were traded. BDSX stock price reached its highest trading level at $0.5402 during the session, while it also had its lowest trading level at $0.4101.
Ratios:
We take a closer look at BDSX’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 2.03 and its Current Ratio is at 2.14. In the meantime, Its Debt-to-Equity ratio is 63.28 whereas as Long-Term Debt/Eq ratio is at 62.18.
On July 26, 2024, Craig Hallum started tracking the stock assigning a Buy rating and target price of $3.Craig Hallum initiated its Buy rating on July 26, 2024, with a $3 target price.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Aug 29 ’25 when SCHULER JACK W bought 3,488,372 shares for $0.43 per share. The transaction valued at 1,500,000 led to the insider holds 24,406,546 shares of the business.
Cowie Robin Harper sold 988 shares of BDSX for $411 on Aug 13 ’25. The CFO, Sec’y & Treasurer now owns 250,794 shares after completing the transaction at $0.42 per share. On Aug 13 ’25, another insider, Hutton Scott, who serves as the President & CEO of the company, sold 3,772 shares for $0.42 each. As a result, the insider received 1,570 and left with 728,824 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, BDSX now has a Market Capitalization of 65002408 and an Enterprise Value of 117744368. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.85 while its Price-to-Book (P/B) ratio in mrq is 57.13. Its current Enterprise Value per Revenue stands at 1.538 whereas that against EBITDA is -4.194.
Stock Price History:
The Beta on a monthly basis for BDSX is 0.99, which has changed by -0.76054054 over the last 52 weeks, in comparison to a change of 0.20221436 over the same period for the S&P500. Over the past 52 weeks, BDSX has reached a high of $1.91, while it has fallen to a 52-week low of $0.17. The 50-Day Moving Average of the stock is 19.15%, while the 200-Day Moving Average is calculated to be -38.39%.
Shares Statistics:
According to the various share statistics, BDSX traded on average about 1.74M shares per day over the past 3-months and 9202820 shares per day over the past 10 days. A total of 146.58M shares are outstanding, with a floating share count of 69.38M. Insiders hold about 52.69% of the company’s shares, while institutions hold 24.29% stake in the company. Shares short for BDSX as of 1755216000 were 3768020 with a Short Ratio of 2.16, compared to 1752537600 on 4280989. Therefore, it implies a Short% of Shares Outstanding of 3768020 and a Short% of Float of 5.06.
Earnings Estimates
The stock of Biodesix Inc (BDSX) is currently drawing attention from 4.0 analysts actively involved in the ongoing evaluation and rating process.The consensus estimate for the next quarter is -$0.05, with high estimates of -$0.05 and low estimates of -$0.06.
Analysts are recommending an EPS of between -$0.27 and -$0.29 for the fiscal current year, implying an average EPS of -$0.28. EPS for the following year is -$0.17, with 5.0 analysts recommending between -$0.14 and -$0.23.
Revenue Estimates
According to 5 analysts, the current quarter’s revenue is expected to be $20.98M. It ranges from a high estimate of $21.6M to a low estimate of $19.9M. As of the current estimate, Biodesix Inc’s year-ago sales were $18.15MFor the next quarter, 5 analysts are estimating revenue of $24.3M. There is a high estimate of $25.8M for the next quarter, whereas the lowest estimate is $23.1M.
A total of 5 analysts have provided revenue estimates for BDSX’s current fiscal year. The highest revenue estimate was $85M, while the lowest revenue estimate was $81M, resulting in an average revenue estimate of $83.06M. In the same quarter a year ago, actual revenue was $71.32MBased on 5 analysts’ estimates, the company’s revenue will be $105M in the next fiscal year. The high estimate is $111.8M and the low estimate is $97.5M.
